SNSE.NASDAQSensei Biotherapeutics, INC

Form 4: Sensei Biotherapeutics CEO John Celebi Reports Stock Transaction

Sentiment:

SEC Form 4 Filing

📋All filings for Sensei Biotherapeutics, INC
🔒Login to Follow

John Celebi, CEO of Sensei Biotherapeutics, reports disposition of shares to cover tax obligations and accumulation of shares through the employee stock purchase plan.

Summary

  • John Celebi, the President and CEO of Sensei Biotherapeutics, filed a Form 4 on February 26, 2025.
  • The report details a transaction on February 19, 2025, where 5,558 shares of common stock were disposed of to satisfy withholding tax obligations at a price of $0.476 per share.
  • Following the transaction, Celebi directly owns 105,862 shares of Sensei Biotherapeutics.
  • This includes 6,000 shares purchased since May 16, 2024, through the company's 2021 Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to tax obligations and participation in the employee stock purchase plan, indicating standard executive compensation practices.

Positives

  • The CEO's participation in the Employee Stock Purchase Plan indicates confidence in the company's future.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which can be a signal to investors.

Stakeholder Impact

  • The transaction provides transparency to shareholders regarding insider trading activity.

Key Dates

DateDescription
May 16, 2024Start date for shares purchased through the Employee Stock Purchase Plan.
February 19, 2025Date of stock disposal for tax obligations.
February 26, 2025Form 4 filing date.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.